Male Infertility

Male infertility is a disease of the male reproductive system, caused primarily by congenital and genetic conditions, anatomical, endocrine, functional or immunological abnormalities of the reproductive tract, genital tract infections, cancer and its treatments, and sexual disorders that preclude intercourse ^[7]D5. Inadequate lifestyle, toxicant exposure, and advanced paternal age act as critical modifiers that can exacerbate underlying causes ^[7]D5.

Also Called & Synonyms

• Male factor infertility (preferred term in ART literature)
• Male subfertility (used when conception is delayed but not impossible)
• Andrological infertility (clinical specialty term)

Defining Key Terms

Every stage of the diagnostic pathway uses standardized terminology. The core outcome set for infertility research defines clinical pregnancy as evidence of a gestational sac on ultrasound and live birth as delivery of a live infant after 22 weeks ^[4]D5. For semen analysis, the EAU guidelines rely on WHO reference limits, categorizing men as having azoospermia (no sperm in ejaculate), oligozoospermia (low sperm count), asthenozoospermia (low motility), teratozoospermia (abnormal morphology), or combinations thereof ^[1]A1c.

Azoospermia is further split into obstructive azoospermia (OA) - a blockage in the ductal system - and nonobstructive azoospermia (NOA) - a primary testicular failure of spermatogenesis ^[2]C4. In a universal health-care cohort, OA accounted for 29% and NOA for 71% of azoospermic men ^[2]C4.

Classification Systems

Urologists use two complementary frameworks to triage and treat:

The APHRODITE criteria were designed to standardize patient stratification for clinical trials and hormonal therapy ^[6]D5.

Clinical Significance

Male factor infertility is not a benign condition. In a nationally representative U.S. sample, men with a diagnosis of infertility had a high burden of comorbidities: 3.4% had cancer, 7.9% diabetes, 8.8% depression, and 30.3% were active tobacco users ^[5]B2c. Over 3.4 million ambulatory visits for male infertility occurred between 2006 and 2016, yet more than half of these men were seen by non-urologists, highlighting a gap in specialized care ^[5]B2c.

Pearl: The first step in managing azoospermia is to distinguish obstructive from nonobstructive causes - a single FSH level and a careful testicular exam (measuring volume and palpating the vas) can guide the need for genetic testing, testicular biopsy, or surgical sperm retrieval. Do not label a man as having NOA without a hormonal profile and genetic screen.

From this classification framework, the pathogenic mechanisms of male infertility converge on a few core pathways: impaired spermatogenesis, ductal obstruction, and dysregulated sperm function. The mechanistic spine is best understood along the axes of genetic integrity, thermal and oxidative stress, inflammatory disruption, and obstructive anatomy.

Spermatogenic Failure: Genetic and Epigenetic Mechanisms

Defects in germ cell development account for the majority of nonobstructive azoospermia (NOA). Y-chromosome microdeletions, particularly in the azoospermia factor (AZF) regions, are found in 4% of infertile men, with AZFc deletions comprising 75% of cases ^[16]B3b. A sperm concentration threshold of <0.5 million/mL retains 100% sensitivity for detecting these deletions ^[16]B3b. Beyond structural deletions, disruption of the N6-methyladenosine (m6A) epitranscriptome, for example, biallelic PRRC2A variants, impairs meiotic progression and histone-to-protamine transition, leading to meiotic arrest and severely compromised DNA integrity ^[32]C4. Autosomal recessive conditions such as cystic fibrosis, caused by CFTR mutations, produce congenital bilateral absence of the vas deferens (CBAVD) as a primary obstructive mechanism ^[17]D5.

Oxidative Stress and the Varicocele Paradigm

Varicocele is the most surgically correctable cause of male infertility and operates through a cascade of heat stress, oxidative injury, and apoptosis. The pampiniform plexus normally contains a complex smooth muscle architecture with a longitudinal adventitial layer that facilitates venous return; this layer is progressively degraded in varicocele, disappearing entirely in grade III disease ^[10]B3b. The resultant venous stasis elevates scrotal temperature (ΔT), which directly correlates with the generation of 4-hydroxy-2-nonenal (4-HNE)-modified proteins, a marker of lipid peroxidation, and with cleavage of caspase-3 and PARP, confirming apoptosis as the terminal event ^[22]C4. The magnitude of ΔT, not varicocele grade, predicts the degree of oxidative stress and germ cell loss ^[22]C4. This oxidative environment is compounded by a dysregulated lactate-lactylation axis: in varicocele-associated asthenozoospermia, intracellular L-lactate is depleted while seminal plasma lactate rises, and global protein lactylation, particularly of flagellar and glycolytic proteins (TEKT3, AKAP4, TUBA1A), is reduced ^[31]C4.

Inflammatory and Immunologic Pathways

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) impairs fertility through multiple intersecting mechanisms. Pro-inflammatory cytokines (IL-6, TNF-α) directly damage mitochondrial function and sperm DNA integrity, increasing DNA fragmentation rates >30% ^[19]D5. Neuroendocrine dysregulation suppresses the hypothalamic-pituitary-testicular axis, and metabolic syndrome comorbidity (OR 2.10) exacerbates an energy crisis via mitochondrial dysfunction ^[19]D5. Gut microbiota dysbiosis reduces anti-inflammatory short-chain fatty acids, intensifying systemic and reproductive tract inflammation ^[19]D5. Antisperm antibodies (ASA) represent another immune-mediated barrier: serum IgG against sperm tails has 85% sensitivity and 97% specificity for obstructive azoospermia, especially after vasectomy , and can obviate the need for testicular biopsy ^[13]B3b.

The Final Common Pathway: Oxidative Stress

Reactive oxygen species (ROS) serve as a unifying pathogenic mediator. Seminal ROS levels rise with age, becoming significantly higher after age 40, and correlate negatively with sperm concentration and motility ^[28]B2b. In hemodialysis patients, testicular volume declines in a dialysis-duration-dependent manner, driven by 3.1-fold increased 4-HNE generation, reduced proliferating cell nuclear antigen expression, and progressive interstitial fibrosis ^[14]B3b. The balance between ROS production and antioxidant capacity determines whether ROS act as physiologic signaling molecules or induce DNA damage, lipid peroxidation, and apoptosis ^[20]D5. Protamine 2 (PRM2) gene expression is decreased in immature sperm, with concurrent elevation of caspase 9 activity, linking defective chromatin packaging to apoptotic activation ^[12]D5.

Emerging Mechanistic Concepts

Multi-omics profiling has identified differentially expressed proteins in idiopathic asthenozoospermia, including GRP78, DJ-1, and GPX4, that implicate unfolded protein response, oxidative defense, and energy metabolism in motility failure ^[21]B3b. The semen microbiome shows distinct dysbiosis in infertile men: increased seminal α-diversity, increased Aerococcus, and decreased rectal Anaerococcus; Prevotella abundance inversely correlates with sperm concentration ^[9]B3b. Metagenomic analysis reveals alterations in the S-adenosyl-L-methionine cycle, which may affect DNA methylation, polyamine synthesis, and oxidative stress simultaneously ^[9]B3b.

Pearl: The final common pathway of most pathogenic mechanisms, varicocele, aging, infection, genetic defects, is oxidative stress-induced apoptosis of germ cells, making scrotal temperature and seminal ROS levels central modifiable targets.

From the molecular pathways that govern spermatogenesis, the clinician must now turn to the population-level burden of male infertility and the factors that drive it. Male factor contributes to approximately 50% of infertility cases, with a prevalence of 7-15% among couples attempting conception ^[40]D5[50]C4. In a prospective cohort of 800 male partners, primary spermatogenic failure accounted for 56.0%, infection/inflammation for 22.4%, and hypogonadotropic hypogonadism for 8.5%; after comprehensive workup, only 5.3% remained idiopathic ^[53]B2b.

Demographic and Geographic Variation

Prevalence varies by region and ethnicity. In a multi-ethnic London cohort, Y-chromosome microdeletions were found in 4% of infertile men ^[16]B3b. Among Omani couples, male-factor infertility was identified in 41.7% of cases, with oligospermia (45.4%) and azoospermia (11.1%) as the most common semen abnormalities ^[50]C4. In East Indian men, chromosomal polymorphic variants were significantly elevated (24% vs. controls, p<0.05) ^[51]B3b. Age is a modest risk factor; female partner age >35 years amplifies the impact of male subfertility ^[50]C4.

Risk Factors

Genetic and Congenital Factors

Chromosomal abnormalities are found in 8.2% of infertile men, with Klinefelter syndrome (47,XXY) comprising 49% of these ^[39]C4. Y-chromosome microdeletions are almost exclusively AZFc deletions; the threshold for screening should be ≤1 million sperm/mL to capture 100% of deletions while increasing specificity ^{[37]C4[16]B3b}. DAZ1/DAZ2 copy deletions are specifically associated with spermatogenic impairment in South Chinese populations ^[44]B3b.

Environmental and Lifestyle Factors

Cigarette smoking exerts a dose-dependent negative effect on semen parameters, with moderate/heavy smokers showing greater impairment ^[36]B2a. Air pollution is a modifiable risk factor, with consistent modest reductions in motility and morphology ^[49]B2a. Anabolic steroid abuse is increasingly prevalent (up to 3 million users in the US) and causes prolonged or permanent spermatogenic failure ^[40]D5.

Pearl: The single most actionable threshold from epidemiology : Y-chromosome microdeletion testing should be reserved for men with sperm concentration ≤1 million/mL, as only 0.8% of men with >1 million/mL harbor a deletion ^[37]C4.

From the epidemiological landscape of risk factors, the clinician now turns to the patient's story and physical findings that signal male infertility. Most men present with inability to conceive after 12 months of unprotected intercourse, but many are asymptomatic and discovered during couple evaluation. Sexual dysfunction, erectile dysfunction , ejaculatory disorders, or low libido, may both contribute to and result from infertility, warranting a detailed sexual history ^[54]D5. Others report symptoms of underlying conditions: testicular pain or swelling (varicocele, infection), a history of cryptorchidism , or chronic respiratory symptoms such as sinusitis and wet cough that suggest primary ciliary dyskinesia (PCD) or cystic fibrosis (CF) ^{[62]C4[60]B3b}. Antidepressant use, particularly serotonin reuptake inhibitors, can cause reversible declines in sperm concentration and motility ^[59]C4. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) presents with pelvic pain and is associated with marked reductions in sperm concentration (SMD -14.12), forward motility (SMD -5.94), and normal morphology (SMD -8.26), along with elevated DNA fragmentation rates (>30%) ^[19]D5.

Physical Examination Findings

Scrotal examination is the cornerstone. Measure testicular volume with an orchidometer or ultrasound; volume <12 mL is associated with impaired spermatogenesis ^[55]D5. Palpate for testicular inhomogeneity, cryptorchidism, testicular microlithiasis, and varicocele (graded in standing position with Valsalva). Bilateral absence of the vas deferens suggests CFTR mutation and warrants CF genetic testing ^[60]B3b. Epididymal induration or enlargement may indicate obstruction or inflammation ^[55]D5. Signs of hypogonadism, reduced body hair, gynecomastia , small phallus, should be noted. A digital rectal examination is indicated if prostatic infection or obstruction is suspected.

Phenotypic Variants

Red Flags

• Testicular mass on palpation or ultrasound: suspect malignancy, especially in men with cryptorchidism or testicular microlithiasis ^[55]D5.
• Severe oligospermia or azoospermia with chronic respiratory symptoms: evaluate for CF (sweat chloride, CFTR sequencing) or PCD ^{[60]B3b[62]C4}.
• Rapid onset of hypogonadism (low libido, erectile dysfunction, headache, visual field defects): consider pituitary tumor.
• Unexplained azoospermia with normal testicular volume: rule out obstruction or genetic causes.

Atypical Presentations

Infertility may be the first clue to systemic disease. Men with testicular germ cell tumors often have contralateral hypospermatogenesis, even before treatment ^[56]B3b. Medication-induced infertility (e.g., SSRIs, exogenous testosterone) can present with isolated semen abnormalities without other symptoms ^[59]C4. Post- vasectomy reversal failure may be due to epididymal obstruction or antisperm antibodies. Asymptomatic abnormal semen analysis discovered during routine screening requires a full workup, as underlying causes (varicocele, infection, genetic) are often treatable.

Pearl: A focused history for respiratory symptoms, medication use, and sexual dysfunction, combined with scrotal examination measuring testicular volume and palpating the vas deferens, identifies the cause in most men, and may uncover a systemic disorder requiring multidisciplinary care.

From the clinical presentation, the diagnostic workup proceeds systematically to identify the specific cause of male infertility. The evaluation is guided by evidence-based algorithms from the AUA/ASRM and EAU guidelines, combining history, physical examination, semen analysis, hormonal and genetic testing, and targeted imaging ^{[63]A1c[64]A1c}. The goal is to identify reversible causes, guide treatment, and counsel the couple on prognosis.

History and Physical Examination

A thorough history should cover the duration of infertility (≥12 months), prior fertility, coital frequency, childhood disorders ( cryptorchidism , hernia repair), systemic illnesses (diabetes, cystic fibrosis), medications (anabolic steroids, sulfasalazine, testosterone ), and lifestyle factors (cigarette smoking, cannabis use, excessive heat exposure). Cigarette smoking is associated with reduced sperm count by a mean of 9.72×10⁶/mL (95% CI, -13.32 to -6.12) and decreased motility and morphology ^[36]B2a. Cannabis may reduce sperm count and concentration, with animal models showing testicular atrophy ^[68]D5. Physical examination should assess body habitus (obesity is linked to increased sperm DNA fragmentation ^[80]C4), testicular volume (normal ≥15 mL), presence of varicocele, and vas deferens patency. A clinical varicocele (grade II-III) is the most common correctable cause; elevated scrotal temperature (ΔT) correlates with oxidative stress and apoptosis ^[22]C4. Red flags include testicular masses (found in 2.9% of infertile men on scrotal ultrasound ^[38]B3b) and signs of hypogonadism.

Semen Analysis (Gold Standard)

The gold-standard diagnostic test is a semen analysis performed according to WHO 2010 methods, with two separate samples collected after 2-7 days of abstinence ^[63]A1c. The lower reference limits are: semen volume ≥1.5 mL, sperm concentration ≥15×10⁶/mL, total motility ≥40%, progressive motility ≥32%, and normal morphology ≥4% (strict criteria). A single abnormal result requires confirmation with a second sample after 2-3 months. The test has high specificity but limited sensitivity for predicting fertility; thus, it is the cornerstone but not a standalone test. Sperm DNA fragmentation (TUNEL) testing may be considered in specific cases (e.g., idiopathic infertility, recurrent pregnancy loss ), with a cutoff of 19.25% providing 100% specificity in one study ^[69]B3b, but routine use is not recommended due to lack of standardization and limited clinical impact ^[93]D5.

Laboratory Studies

Hormonal evaluation is indicated in men with abnormal semen analysis, especially if sperm concentration <10×10⁶/mL, or when clinical features suggest endocrinopathy ^[64]A1c. The initial panel includes serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), and total testosterone. An elevated FSH (>12.1 IU/L, the 95th percentile) has a positive predictive value >0.7 for subfertility, but lower FSH levels do not reliably exclude impairment ^[75]B3b. In men with nonobstructive azoospermia, FSH >12.1 IU/L with low testicular volume suggests primary testicular failure. A high FSH (≥7.5 IU/L) is associated with abnormal sperm concentration and morphology ^[79]B2b. Inhibin B, produced by Sertoli cells, correlates with spermatogenesis; a nomogram incorporating testicular volume, FSH, and inhibin B can predict live birth after varicocelectomy ^[41]B2b. Prolactin and estradiol levels are reserved for men with suspected pituitary pathology or gynecomastia . Post- vasectomy men do not require hormonal testing unless planning reversal.

Imaging

Scrotal ultrasound is the first-line imaging modality for all infertile men with abnormal semen analysis or abnormal physical exam ^[64]A1c. It measures testicular volume, detects subclinical varicoceles (with Doppler), and identifies incidental small testicular masses (hypoechoic lesions <10 mm), which occur in 2.9% of infertile men and can be safely surveilled if <5 mm and avascular ^[38]B3b. Transrectal ultrasound (TRUS) is indicated when ejaculate volume is low (<1.5 mL) with normal testicular size, to rule out distal obstruction (e.g., ejaculatory duct cysts, seminal vesicle dilation). Magnetic resonance imaging (MRI) is reserved for complex cases, such as suspected renal agenesis with ipsilateral seminal vesicle pathology ^[8]C4. For men with varicocele, testicular shear wave elastography (SWE) may predict improvement after varicocelectomy: a stiffness cutoff of 4.5 kPa yields 86.4% sensitivity and 84.2% specificity for semen parameter improvement ^[72]C4.

Genetic Testing

Genetic evaluation is essential in men with azoospermia or severe oligozoospermia (sperm concentration <5×10⁶/mL). The EAU and AUA/ASRM guidelines recommend karyotype analysis and Y-chromosome microdeletion (YCM) testing ^{[63]A1c[64]A1c}. A meta-analysis of European and North American studies found that complete YCMs (all AZFc) occur in 5.0% of men with sperm concentration 0-1×10⁶/mL, but only 0.8% in men with >1×10⁶/mL ^[37]C4. The threshold for YCM testing should be ≤1×10⁶ sperm/mL to maximize specificity without sacrificing sensitivity (sensitivity 100%, specificity 31%) ^[16]B3b. Karyotype analysis is indicated in men with azoospermia or severe oligozoospermia, especially if FSH is elevated; it detects Klinefelter syndrome (47,XXY) in 5-10% of azoospermic men ^[73]B3b. CFTR mutation testing is indicated in men with congenital bilateral absence of the vas deferens (CBAVD) or unexplained obstructive azoospermia with low ejaculate volume ^[17]D5. The AUA/ASRM guidelines also recommend genetic counseling for all men with identified genetic abnormalities ^[64]A1c.

Diagnostic Algorithm

1. Step 1: History and physical examination (identify varicocele, cryptorchidism, lifestyle factors, medications).
2. Step 2: Two semen analyses ≥2 weeks apart (WHO 2010 criteria). If both normal → female partner evaluation; if abnormal → proceed.
3. Step 3: Hormonal profile (FSH, LH, testosterone). If FSH >12.1 IU/L or low testosterone → further endocrine workup (prolactin, estradiol, pituitary MRI if indicated).
4. Step 4: Genetic testing: if sperm concentration ≤1×10⁶/mL → YCM testing; if azoospermia or severe oligozoospermia → karyotype; if CBAVD or low volume → CFTR mutation analysis.
5. Step 5: Imaging: scrotal ultrasound for all abnormal semen analyses; TRUS for suspected obstruction; MRI for complex anomalies.
6. Step 6: Specialized testing (e.g., sperm DNA fragmentation, TUNEL) in selected cases (idiopathic infertility, recurrent pregnancy loss, high oxidative stress markers) ^{[69]B3b[93]D5}.

Pearl: The cornerstone of male infertility diagnosis is a properly performed semen analysis, but it must be interpreted in the context of a complete history and physical; isolated abnormalities often require further investigation, and the threshold for genetic testing (YCM) should be sperm concentration ≤1 million/mL, not the traditional 5 million/mL ^{[37]C4[64]A1c}.

Following the diagnostic workup, the clinician must synthesize findings into a risk profile that guides management decisions. This section converts diagnostic data, semen parameters, hormonal levels, imaging, and genetic results, into graded risk tiers that select between surveillance, medical, and surgical pathways.

Varicocele Grading and Risk Stratification

Varicocele is the most common potentially correctable cause of male infertility, and ultrasound (US) is the imaging modality of choice for its evaluation ^[94]A1c. The European Society of Urogenital Radiology (ESUR) Scrotal and Penile Imaging Working Group (ESUR-SPIWG) has issued evidence-based recommendations for standardized US examination technique, interpretation, and classification, though no single grading system has universal acceptance ^[94]A1c. Clinical grading (Dubin-Amelar grades 1-3) and US-based grading (e.g., venous diameter >2.5 mm at rest, reflux duration) stratify severity. Higher-grade varicoceles (grade 3) are associated with greater impairment of semen parameters and higher likelihood of benefit from surgical repair, but even grade 1-2 varicoceles may warrant intervention in the setting of abnormal semen analysis or couple infertility.

Genetic Risk Stratification

The European Association of Urology (EAU) guidelines recommend karyotype analysis (KA) in men with severe oligozoospermia or azoospermia. In a validation cohort of 1168 men, the EAU criteria had a sensitivity of 80%, specificity of 37%, and discrimination of 59% for detecting karyotype alterations ^[73]B3b. Notably, 12 of 60 patients (20%) with karyotype abnormalities would have been missed by strict EAU criteria ^[73]B3b. A novel nomogram using a 2% probability cut-off improved detection, reducing unnecessary testing while capturing more abnormalities ^[73]B3b. This nomogram incorporates clinical variables such as testicular volume, follicle-stimulating hormone (FSH), and inhibin B. For men with azoospermia, Y-chromosome microdeletion testing and CFTR mutation analysis further stratify risk for obstructive versus non-obstructive causes.

Predictive Nomograms for Treatment Outcomes

Risk stratification also predicts treatment success. After microsurgical varicocelectomy (MV), 40.89% of couples achieved live birth within 2 years ^[41]B2b. A nomogram incorporating larger testicular volume, lower FSH, and higher inhibin B demonstrated good discrimination and calibration for predicting live birth ^[41]B2b. Decision curve analysis confirmed clinical utility across a wide range of threshold probabilities ^[41]B2b. For couples pursuing assisted reproductive technology, a nomogram for cumulative live birth after the first IVF cycle includes male infertility as a significant predictor (AUC 0.676, 95% CI 0.668-0.684) ^[95]C4. These tools allow individualized counselling: men with favorable profiles (e.g., testicular volume >15 mL, FSH <8 IU/L, inhibin B >100 pg/mL) have higher chances of natural conception after varicocele repair, while those with poor prognostic markers may proceed directly to ART.

Risk Factors and Lifestyle Stratification

An umbrella review of 43 studies identified 67 risk factors associated with infertility and abnormal semen parameters, with 54 (21.7%) graded as moderate-quality evidence ^[96]B2a. Factors with moderate evidence include type 1 diabetes, metabolic syndrome, hyperthyroidism, systemic lupus erythematosus, chronic prostatitis, leukocytospermia, obesity, sleep disorders, smoking, and exposure to pollutants (carbon disulfide, organophosphates, lead) ^[96]B2a. Medications such as sulfasalazine , mesalazine , and selective serotonin reuptake inhibitors (SSRIs) also impair semen quality ^[96]B2a. Organophosphate pesticide exposure significantly reduces sperm count, concentration, progressive motility, total motility, and normal morphology, though without affecting serum FSH, LH, or testosterone ^[97]B2a. Conversely, regular physical exercise, nut consumption, and adherence to a healthy dietary pattern are protective ^[96]B2a. Stratifying patients by modifiable risk factors enables targeted lifestyle interventions before or alongside medical/surgical therapy.

Proposed Risk Tier Framework

Controversies and Guideline Disagreement

Pearl: A systematic risk stratification integrating varicocele grade, genetic risk, and modifiable factors, using predictive nomograms where available, optimizes the selection of surveillance, medical, or surgical pathways, with the goal of maximizing live birth while minimizing unnecessary interventions.

Building on the risk stratification from the prior section, the acute management of male infertility begins with identifying the specific correctable cause and initiating the most appropriate intervention without delay. The AUA/ASRM guideline (2020) provides a comprehensive algorithm for treatment decisions, emphasizing that the choice of therapy depends on the underlying etiology, the severity of semen abnormalities, and the couple's reproductive goals ^{[65]A1c[101]A1c}.

Step 1: Initial Assessment and Severity Classification

Before any intervention, confirm the diagnosis with a repeat semen analysis, hormonal evaluation (testosterone, FSH, LH), and, if indicated, genetic testing (e.g., Y-chromosome microdeletion, karyotype) ^{[64]A1c[100]A1c}. The AUA/ASRM guideline stratifies patients into those with:

• Obstructive azoospermia (normal FSH, testicular volume, and palpable vas) - candidates for surgical reconstruction.
• Non-obstructive azoospermia (elevated FSH, small testes) - may require sperm retrieval with ICSI or hormonal therapy if hypogonadotropic.
• Severe oligospermia (< 5 million/mL) - often due to varicocele, hormonal imbalance, or genetic causes.

Step 2: First-Line Intervention for Identified Causes

Varicocele - The AUA/ASRM guideline recommends varicocelectomy for men with a clinically palpable varicocele, abnormal semen parameters, and infertility of ≥ 1 year (conditional recommendation, evidence strength C) ^{[65]A1c[101]A1c}. The procedure improves semen parameters in 60-80% of men and may restore natural fertility.

Obstructive azoospermia - Surgical reconstruction via vasovasostomy (if prior vasectomy ) or epididymovasostomy (if epididymal obstruction) is the first-line approach. Patency rates exceed 90% for vasovasostomy when performed within 10 years of vasectomy ^{[65]A1c[101]A1c}.

Hypogonadotropic hypogonadism - Gonadotropin therapy (hCG alone or with FSH) is recommended to stimulate spermatogenesis. The AUA/ASRM guideline notes that this is effective in restoring fertility in the majority of men with this condition (strong recommendation, evidence strength B) ^{[65]A1c[101]A1c}.

Step 3: Second-Line Options When First-Line Fails or Is Not Possible

If surgical reconstruction fails or is not feasible, or if the man has non-obstructive azoospermia, the next step is surgical sperm retrieval (micro-TESE, TESA, PESA) combined with ICSI. The AUA/ASRM guideline supports this as a standard approach (moderate recommendation, evidence strength C) ^{[65]A1c[101]A1c}.

For idiopathic oligospermia without clear cause, the guideline notes that empiric medical therapy (e.g., clomiphene, anastrozole) is of uncertain benefit and should be considered only after discussion of limited evidence ^{[65]A1c[101]A1c}.

Step 4: Monitoring and Titration

After treatment, monitor semen parameters every 3 months until pregnancy is achieved or a plateau is reached. For hormonal therapy, check testosterone, LH, and FSH levels at 3-month intervals to adjust dosing ^{[65]A1c[101]A1c}. If no improvement is seen after 6-12 months, escalate to assisted reproductive techniques.

Step 5: Resolution and Transition to Long-Term Management

If natural conception occurs or the couple achieves pregnancy via IUI, IVF, or ICSI, acute management is complete. Otherwise, the patient transitions to long-term definitive management (covered in the next section), which may include repeated surgical interventions, advanced ART, or consideration of donor sperm.

What NOT to Do

The AUA/ASRM guideline advises against routine use of empiric hormonal therapy for men with non-obstructive azoospermia and normal FSH, as it does not improve outcomes ^{[65]A1c[101]A1c}. Additionally, varicocelectomy is not recommended for men with subclinical varicocele (detected only by ultrasound) or normal semen parameters ^{[65]A1c[101]A1c}.

Controversies and Guideline Disagreement

No major guideline disagreements were identified among the reviewed evidence for the acute management of male infertility. The AUA/ASRM recommendations are consistent with other international guidelines, though the evidence strength for many recommendations is limited (C) due to the lack of large randomized trials ^{[65]A1c[101]A1c}.

Pearl: The most effective acute interventions for male infertility are varicocelectomy for clinical varicocele and surgical reconstruction for obstructive azoospermia, both of which offer the best chance for natural conception as recommended by the AUA/ASRM guideline ^{[65]A1c[101]A1c}.

Once acute conditions such as testicular torsion or infection are managed, the clinician must formulate a long-term plan tailored to the specific cause of infertility. The evidence ladder now guides a choice between medical therapy, surgical correction of correctable lesions, and assisted reproductive techniques (ART), each with quantifiable effect sizes.

Medical Therapy for Idiopathic and Varicocele-Associated Infertility

Antioxidant supplementation targets oxidative stress, a common final pathway in spermatogenic failure. A double-blind RCT (N=468) of men with idiopathic oligo-asthenoteratospermia found that selenium 200 µg daily plus N-acetyl-cysteine (NAC) 600 mg daily for 26 weeks significantly improved sperm concentration, motility, and morphology versus placebo, with additive effects when combined ^[107]A1b (1b). A separate RCT (N=120) confirmed that NAC 600 mg/day for 3 months improved semen volume, motility, and viscosity, alongside increased total antioxidant capacity ^[110]C4 (4). In a double-blind trial of 104 men with oligoasthenoteratozoospermia (with or without varicocele), supplementation with L-carnitine, acetyl-L-carnitine, vitamins, and other nutrients significantly increased sperm concentration (P=0.0186), total sperm count (P=0.0117), and motility (P=0.0120), with greater benefit in men ≤35 years and normal BMI ^[117]A1b (1b).

Hormonal therapy with aromatase inhibitors targets the estradiol‑testosterone imbalance in spermatogenic failure. In a multicenter RCT (N=296) of men with nonobstructive azoospermia (NOA), cryptozoospermia, or severe oligozoospermia, letrozole 2.5 mg daily plus vitamins C/E for 3 months achieved a WHO sperm concentration category upgrade rate of 14.3% versus 5.4% with vitamins alone (risk difference 9.2%, 95% CI 2.5%-15.8%; P=0.01; NNT ≈ 11) ^[84]A1b (1b). Letrozole also increased gonadotropins and testosterone while decreasing estradiol; decreased libido was more frequent (12.2% vs 5.4%).

Denosumab, a RANKL inhibitor, failed to improve sperm concentration in two placebo‑controlled RCTs. In men with severe oligospermia (N=42), a single 60 mg subcutaneous dose showed no difference at day 80 ^[113]A1b (1b). A larger trial (N=179) selecting men with serum AMH ≥38 pmol/L also found no benefit overall, though an exploratory subgroup (testis ≤16 mL, no cryptorchidism ) showed a 29% increase in sperm concentration ^[114]A1b (1b). Denosumab is not recommended for routine use.

Surgical Management of Varicocele

Varicocele repair is indicated in infertile men with a palpable varicocele and at least one impaired semen parameter. A landmark RCT (N=145) demonstrated that subinguinal microsurgical varicocelectomy increased spontaneous pregnancy from 13.9% to 32.9% over 12 months (OR 3.04, 95%; NNT = 5.3) and significantly improved all semen parameters versus observation ^[106]A1b (1b). A comparative RCT (N=298) of open inguinal, laparoscopic, and subinguinal microsurgical varicocelectomy found that microsurgery had the lowest recurrence rate (2.6% vs 11% open vs 17% laparoscopy) and zero hydrocele formation, with superior improvement in sperm count and motility ^[34]A1b (1b). Postoperative scar appearance can be improved with silicone gel applied twice daily for 60 days, which significantly reduced vascularity, pigmentation, pliability, height, and pruritus (P<0.05) ^[112]A1b (1b).

Sperm Retrieval Techniques for Azoospermia

For men with NOA, the choice of retrieval technique directly affects sperm retrieval rate (SRR). A multicenter RCT (N=100) comparing microdissection testicular sperm extraction (mTESE) with multiple needle‑pass testicular sperm aspiration (TESA) found SRR of 43% for mTESE versus 22% for TESA (rate difference -0.21, 95% CI -0.39 to -0.03; P=0.02; NNT = 4.8) ^[66]A1b (1b). Salvage mTESE after failed TESA raised the combined SRR to 29%. Complications requiring surgical intervention occurred in 6% of mTESE procedures versus none with TESA alone ^[66]A1b.

Assisted Reproductive Technologies

In couples with non‑severe male factor infertility, a large RCT (N=2387) found that intracytoplasmic sperm injection (ICSI) did not improve live birth rate compared with conventional IVF (33.8% vs 36.6%; adjusted RR 0.92) ^[108]A1b (1b). Routine ICSI is not recommended in this population. For severe male infertility, preimplantation genetic testing for aneuploidies (PGT‑A) did not improve live birth after first transfer (48.4% vs 46.2%; OR 1.09, 95% CI 0.76-1.58) or cumulative live birth (60.4% vs 60.9%; OR 0.98, 95% CI 0.67-1.43) in an RCT (N=450), but it significantly reduced pregnancy loss (5.8% vs 19.1%; OR 0.26, 95% CI 0.14-0.50; NNT = 7.5) ^[111]A1b (1b).

Controversies and Guideline Disagreement

Pearl: For palpable varicocele with impaired semen, microsurgical varicocelectomy yields a spontaneous pregnancy rate of 33% (NNT 5.3) ^[106]A1b; for NOA, mTESE retrieves sperm in 43% of men (NNT 4.8) ^[66]A1b; letrozole 2.5 mg daily upgrades sperm concentration categories in 14% of men with spermatogenic failure (NNT 11) ^[84]A1b; routine ICSI for non‑severe male factor does not improve live birth over IVF ^[108]A1b.

The management choices outlined in the preceding section, medical versus surgical, rest on a foundation of landmark trials that have, over the past three decades, defined the current standard of care and relegated older, ineffective therapies to history. The evolution of male infertility treatment is a story of replacing empirical regimens with procedure-specific evidence, from microsurgical varicocelectomy to targeted sperm retrieval and the judicious use of assisted reproduction.

Varicocele Repair: The Microsurgical Revolution

Early randomized evidence was conflicting. The 2010 RCT by Abdel‑Meguid et al. provided level 1b evidence of superiority: spontaneous pregnancy occurred in 32.9% of treated men versus 13.9% of observed controls (OR 3.04, 95%; NNT 5.27) ^[106]A1b. A meta-analysis of four RCTs yielded a combined OR of 2.23 (95%, p = 0.091) that was not statistically significant, but the same analysis showed clear improvements in semen parameters: sperm concentration increased by a mean of 12.32 million/mL and total motility by 10.86% ^[67]A1a. The 2008 randomized comparison by Al‑Said et al. established that microsurgical subinguinal varicocelectomy is superior to open and laparoscopic approaches: recurrence was 2.6% versus 11% and 17%, respectively, and hydrocele formation was 0% versus 2.8% and 5.4% ^[34]A1b. The 1998 prospective study by Barbalias et al. confirmed that the subinguinal approach produced the most prominent improvements in sperm concentration and motility ^[119]A1b. These data together made microsurgical varicocelectomy the gold standard, endorsed by the 2025 EAU guidelines ^[1]A1c.

Sperm Retrieval: From MESA to mTESE

Before the era of microdissection, men with nonobstructive azoospermia (NOA) had few options. Microsurgical epididymal sperm aspiration (MESA) combined with IVF achieved fertilization rates of 79% and clinical pregnancy rates of 35.7% ^[132]D5. The 2022 randomized clinical trial by Jensen et al. directly compared microdissection TESE (mTESE) with multiple needle‑pass testicular sperm aspiration (TESA) in 100 men with NOA. The sperm retrieval rate was 43% for mTESE versus 22% for TESA (rate difference -0.21, 95% CI -0.39 to -0.03; p = 0.02) ^[66]A1b. Salvage mTESE after failed TESA raised the combined retrieval rate to 29%. Complications requiring surgical intervention occurred in 6% of mTESE procedures; none occurred after TESA alone ^[66]A1b. mTESE is now the preferred technique for NOA ^{[1]A1c[118]A1c}.

ICSI: Expanding Use and Its Limits

Intracytoplasmic sperm injection (ICSI) was introduced in 1992 for severe male infertility but its use expanded to non‑severe cases. The 2024 multicenter RCT by Wang et al. randomized 2387 couples with non‑severe male factor to ICSI or conventional IVF. Live birth after first embryo transfer occurred in 33.8% with ICSI versus 36.6% with conventional IVF (adjusted RR 0.92) ^[108]A1b. The trial concluded that routine ICSI in this population does not improve outcomes and may increase costs and risks, including a reported 0.2% neonatal death rate with ICSI ^[108]A1b.

Medical Therapies: Abandoned and Emerging

Abandoned therapies. Androgens were widely used for idiopathic oligoasthenoteratospermia, but a Cochrane review of 11 trials (930 patients) found no benefit; exogenous testosterone suppresses pituitary gonadotropins and can actually impair spermatogenesis ^{[124]A1a[125]A1a[127]D5}. Bromocriptine, tested in four crossover trials, reduced prolactin levels but had no effect on sperm parameters or pregnancy rates ^[126]A1a. Artificial spermatocele implantation yielded 0% pregnancy ^[132]D5.

Emerging therapies. Aromatase inhibitors have gained traction. Letrozole 2.5 mg daily for 3 months, studied in a 2026 multicenter RCT of 296 men with spermatogenic failure, produced a WHO sperm concentration category upgrade rate of 14.3% versus 5.4% in controls (risk difference 9.2%, 95% CI 2.5%-15.8%; p = 0.01) ^[84]A1b. Testolactone and anastrozole improve the testosterone‑to‑estradiol ratio and sperm parameters in men with a low ratio ^[121]B3b. Clomiphene citrate 50 mg daily or every other day raises testosterone by a mean of 200 ng/dL without elevating PSA or hematocrit ^[81]C4. Antioxidants, selenium 200 μg plus N‑acetylcysteine 600 mg daily, improved all semen parameters ^[107]A1b; a 2026 meta‑analysis of 101 studies (11,889 men) confirmed higher sperm concentration (SMD 2.33) and total motility (SMD 1.62) with antioxidant therapy, but the authors stopped short of a definitive recommendation ^[90]B2a.

Obstructive Azoospermia: Reconstruction and Resection

Vasovasostomy yields patency in 81.3% and fertility in 37.5%; epididymovasostomy yields 71% patency and 29% fertility ^[132]D5. Transurethral resection of ejaculatory ducts in men with obstruction raised mean sperm count from 1.66 × 10⁶/mL to 25.4 × 10⁶/mL (p = 0.001) ^{[120]C4[129]C4}. These techniques remain central for reconstructable obstruction, while unreconstructable cases rely on sperm retrieval and ART.

Pearl: The history of male infertility treatment teaches that interventions without proven benefit, androgens, bromocriptine, artificial spermatocele, have been replaced by evidence‑based approaches: microsurgical varicocelectomy (NNT 5.27 for spontaneous pregnancy), mTESE for NOA (SRR 43%), and targeted use of aromatase inhibitors, while ICSI should not be substituted for conventional IVF in non‑severe male factor.

Controversies and Guideline Disagreement

The evolution of surgical technique has refined the approach to varicocele repair and sperm retrieval, with microsurgical methods now representing the standard of care for most indications. Operative judgment, instrument choice, access route, and intraoperative decision nodes, directly determines success rates and morbidity.

Varicocelectomy: Open, Laparoscopic, and Microsurgical Approaches

A randomized trial of 298 infertile men (446 varicoceles) compared open inguinal, laparoscopic, and subinguinal microsurgical varicocelectomy ^[34]A1b. Microsurgical varicocelectomy had the lowest recurrence rate (2.6% vs 11% open vs 17% laparoscopic) and eliminated hydrocele formation (0% vs 2.8% open vs 5.4% laparoscopic) ^[34]A1b. Sperm concentration, motility, and morphology improved significantly in all groups, but the proportion of men with improved count and motility was highest after microsurgery ^[34]A1b. Operative time was longest in the microscopic group, yet the superior outcomes justify the additional time. The subinguinal approach avoids opening the external oblique fascia, reducing postoperative pain and recovery time. Microsurgical subinguinal varicocelectomy is the preferred technique for men with clinical varicocele and abnormal semen parameters or hypogonadism.

Varicocelectomy also raises serum testosterone in hypogonadal men: a meta-analysis of 18 studies (1,225 patients) found a mean increase of 113.87 ng/dL (95%; p<0.00001) ^[150]A1a. Erectile function scores improved by a mean of 3.25 points (95%; p=0.0003) ^[150]A1a.

Sperm Retrieval Techniques: mTESE vs TESA

For men with nonobstructive azoospermia (NOA), the choice of sperm retrieval technique critically affects success. A randomized trial of 100 men with NOA compared microdissection testicular sperm extraction (mTESE) to multiple needle-pass testicular sperm aspiration (TESA) ^[66]A1b. Sperm retrieval rate (SRR) was 43% (21/49) after mTESE vs 22% (11/51) after TESA (rate difference -0.21; 95% CI -0.39 to -0.03; p=0.02) ^[66]A1b. The combined SRR for TESA plus salvage mTESE was 29% (15/51) ^[66]A1b. No complications occurred after TESA alone, while 6% (5/89) of men undergoing mTESE required surgical intervention for a complication ^[66]A1b. Reproductive hormones did not differ significantly between groups at 6 months ^[66]A1b. mTESE offers a higher SRR but carries a small risk of surgical complications; TESA is simpler and safer but less effective. The decision should balance patient preference, surgeon experience, and the likelihood of finding sperm based on preoperative histology and genetic factors.

Epididymovasostomy and Vasovasostomy

For obstructive azoospermia, microsurgical reconstruction aims to restore patency. A novel one-layer epididymovasostomy technique, opening a window in the epididymal tunica, fixing the tubule edges with four 10/0 nylon sutures, then anastomosing the vas to the epididymal opening, achieved sperm in the ejaculate in 6 of 9 patients (67%) with a mean operative time of 176 ± 23 minutes ^[78]C4. This single-layer method simplifies the procedure while maintaining reasonable outcomes. Vasovasostomy, typically performed as a two-layer microsurgical anastomosis, achieves patency rates >90% when performed by experienced surgeons. The key intraoperative decision is whether to perform vasovasostomy or epididymovasostomy, determined by the quality of fluid expressed from the testicular end of the vas: if sperm are present, vasovasostomy is appropriate; if not, epididymovasostomy is indicated.

Endovascular Embolization

In paediatric and adolescent patients, endovascular embolization of the testicular vein offers a minimally invasive alternative. A 14-year cohort of 84 patients (median age 14 years) reported technical success of 94% and clinical success of 98% , with 86% reporting excellent long-term progress and no relapses ^[154]B2b. Embolization avoids a scrotal incision and may be preferred for patients with recurrent varicocele after surgery or those who desire the shortest recovery. However, it does not allow concurrent ligation of collateral veins, and recurrence rates may be higher than with microsurgical repair in adults.

Training and Access Considerations

Microsurgical skills are essential for optimal outcomes in varicocelectomy, vasovasostomy, and mTESE. A review of microsurgical education highlights the need for dedicated training laboratories, artificial and animal models, and technological advancements to improve proficiency and interest in reproductive urology ^[157]D5. Despite the effectiveness of these procedures, access remains limited: only 11% of fertility clinics in the United States have an on-site urologist, and practice size and proximity to an andrology fellowship program are the strongest predictors of urologic referral ^[155]B2c. Barriers include geographic distance, insurance coverage gaps, and low rates of male infertility evaluation (only 50% of potentially infertile men undergo evaluation) ^{[156]D5[158]B2c}. Surgeons must advocate for expanded training and improved access to ensure that evidence-based procedural techniques reach the patients who need them.

Pearl: For varicocelectomy, microsurgical subinguinal repair yields the lowest recurrence and zero hydrocele; for NOA sperm retrieval, mTESE doubles the SRR over TESA but carries a 6% risk of surgical complication, counsel patients accordingly.

Procedural success rates must be weighed against the complication profile of each intervention. Both the underlying disease and its treatment can impair male reproductive potential, and a systematic understanding of these complications drives informed consent and postoperative surveillance.

Varicocele Repair

Varicocelectomy improves sperm concentration by a mean 12.32 million/mL and total motility by 10.86% (both p<0.0001), but the benefit depends on the technique ^[67]A1a. A microsurgical approach yields the lowest recurrence (0-5% versus 5-15% for non-microsurgical ligation) and fewer complications overall ^{[67]A1a[167]B2a}. Venous shunting (spermatic-inferior epigastric vein anastomosis) shows recurrence rates of 0-5% but longer operative times (99-146 min vs 48-92 min) and requires advanced microsurgical expertise; it remains experimental ^[167]B2a. Radiological embolisation improves pain scores and sperm parameters, with recurrence rates comparable whether coils are used alone or with sclerosants ^[168]B2a. The most common post-procedural issues are scrotal edema and hydrocele formation; major complications are rare ^{[167]B2a[168]B2a}.

Microsurgical Sperm Retrieval

In non-obstructive azoospermia, microsurgical testicular sperm extraction (m-TeSE) and loupe-assisted TeSE (l-TeSE) have similar sperm retrieval rates (22.6% overall), with no intraoperative complications recorded. Postoperative events are Clavien-Dindo grade I only (e.g., minimal scrotal discomfort), and no significant difference exists between the two approaches ^[163]A1b. The median time saving of 8 min with l-TeSE (p<0.01) does not compromise safety ^[163]A1b.

Medical Therapy for Idiopathic Infertility

Oestrogen antagonists (clomiphene or tamoxifen) increase spontaneous pregnancy rates (OR 2.42) and improve sperm concentration (weighted mean difference 5.24 million/mL) and motility (4.55%). Adverse events are not significantly different from controls ^[164]A1a. No serious drug-related complications have been reported in the meta-analysis.

Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer

Intravesical BCG can cause transient impairments in semen parameters and sexual function, likely due to local inflammation rather than systemic toxicity ^[166]D5. Genitourinary complications such as epididymo-orchitis and prostatitis may further compromise the male reproductive tract ^[166]D5. Intravesical chemotherapy has minimal systemic absorption but concerns about gonadotoxicity persist; newer agents (nadofaragene, nogapendekin alfa inbakicept-pmln) lack fertility-related safety data ^[166]D5.

Disease-Associated Complications

Certain conditions underlying male infertility carry their own complications. Leydig cell tumors are associated with cryptorchidism (χ²=28.27, p<0.001), gynecomastia (χ²=54.22, p<0.001), lower testicular volume, and impaired semen parameters ^[165]B2b. In a prospective cohort, 38.5% of patients were managed with active surveillance alone, which appears safe for compliant patients ^[165]B2b. Varicocele itself induces testicular hypoxia via upregulation of hypoxia-inducible factor-1α (7-fold higher in affected internal spermatic veins), potentially perpetuating infertility ^[161]B3b.

Complication Overview

Pearl: Microsurgical varicocelectomy reduces recurrence to 0-5%, and the majority of complications from male infertility treatments are minor and self-limited; surveillance and counseling should focus on the specific risks of the chosen intervention.

Having reviewed the complications that may arise from treatment, the clinician must now understand the natural history of male infertility, both untreated and after intervention, to provide realistic counseling. The trajectory of fertility and long-term health varies substantially by etiology, but several consistent patterns emerge from the data.

Natural History of Untreated Male Infertility

Without treatment, spontaneous pregnancy rates in couples with male factor infertility are low. In men with clinical varicocele and isolated asthenospermia who chose observation, the spontaneous pregnancy rate was 32% over follow-up, compared to 65% after varicocelectomy ^[74]B3b. For oligospermic men with varicocele, the natural pregnancy rate was 30% in untreated couples versus 38% after surgery ^[170]B2b. In bilateral varicocele, the difference was more pronounced: 15% untreated vs 48% after repair ^[170]B2b. These data underscore that while spontaneous conception is possible, surgery substantially improves the odds. Notably, the overall efficacy rate of varicocelectomy, defined as improvement in semen parameters or pregnancy, is **62.8% ** ^[71]B2a.

Prognosis After Varicocele Repair

Varicocelectomy improves sperm count by a mean **12.32 million sperm per mL **, total motility by **10.86% **, and progressive motility by **9.69% ** ^[67]A1a. Microsurgical subinguinal repair yields the highest efficacy ^[71]B2a. Within 2 years of microsurgical varicocelectomy, 40.89% of couples achieved a live birth following natural pregnancy ^[41]B2b. In hypogonadal men (total testosterone <300 ng/dL), repair also increases serum testosterone and 17-OH progesterone, with the Δ-17-OHP positively correlating with total motile sperm count improvement (r = 0.388) ^[175]B2b. Adjuvant vitamin E supplementation after varicocelectomy does not provide consistent additional benefit for sperm concentration or motility ^[91]A1a.

Prognosis in Obstructive and Nonobstructive Azoospermia

For obstructive azoospermia, microsurgical epididymovasostomy restores sperm to the ejaculate in approximately 6 of 9 patients (67%) with a new one-layer technique ^[78]C4. For nonobstructive azoospermia (NOA), medical therapy with letrozole 2.5 mg daily for 3 months achieved a WHO Sperm Concentration Category upgrade rate of 14.3% vs 5.4% with placebo (risk difference 9.2%, 95%%; P = 0.01) ^[84]A1b. Testicular sperm aspiration (TESA) in nonazoospermic men yields sperm retrieval in 94% and a clinical pregnancy rate of 35% per cycle ^[47]C4. In men with spinal cord injury, pregnancy and live birth rates after assisted ejaculation and IVF/ICSI are similar to those in non-SCI couples (live birth rate 20.0% vs 27.1%, P not significant) ^[85]B3b.

Mortality Risk and Long-term Health

Male infertility signals elevated all-cause mortality. Compared to fertile men, infertile men have a hazard ratio for death of 1.42 (95% CI 1.27-1.60) ^[174]B2b and a pooled HR of **1.26 ** ^[76]B2a. The risk rises with severity of spermatogenic impairment: azoospermia carries an HR of **2.01 **, and oligospermia an HR of **1.17 ** ^[174]B2b. The pooled risk ratio for death in oligo- and azoospermic men vs normospermic men is **1.67 ** ^[76]B2a. This excess mortality persists after adjusting for prevalent cardiovascular disease and cancer, suggesting that male infertility is an independent marker of overall health ^[174]B2b. Infertile men also have a higher risk of hypogonadism, malignancy, and cardiovascular disease, warranting long-term surveillance ^[169]A1c.

Prognostic Factors and Predictive Models

Preoperative total motile sperm count (OR 3.00) and wider spermatic vein diameter (OR 2.41) predict better outcomes after varicocelectomy ^[71]B2a. A nomogram incorporating testicular volume, follicle-stimulating hormone, and inhibin B accurately predicts live birth after microsurgical varicocelectomy (C-index not reported, but decision curve analysis confirmed clinical utility) ^[41]B2b. Sperm DNA fragmentation testing has limited predictive value for pregnancy or miscarriage (low sensitivity, modest specificity) and should not be used alone for prognosis ^[173]B2a.

When counseling patients, the clinician should integrate these data: the natural history is often poor without intervention, but specific treatments, especially varicocelectomy and assisted reproductive techniques, offer meaningful improvements in fertility and live birth. The elevated mortality risk mandates a broader health assessment beyond fertility. The next section addresses special populations, including men with spinal cord injury, cystic fibrosis, and Klinefelter syndrome , where prognosis and management require tailored approaches.

Pearl: Varicocele repair improves sperm concentration by a mean 12 million/mL and yields a spontaneous live birth rate of ~40% within 2 years; azoospermia carries a 2-fold higher mortality risk, so infertility evaluation doubles as a health screen.

The previous section established that prognosis after varicocelectomy depends on testicular volume, FSH, and inhibin B ^[41]B2b. For special populations, pediatric, pregnant partners, elderly, and immunocompromised men, diagnostic and therapeutic decisions must be adapted to age, comorbidity, and the unique physiologic context of the couple.

Pediatrics

Adolescent varicocele is the most common correctable cause of male infertility in this age group. Although no randomized trials have specifically evaluated pediatric varicocelectomy, evidence from adult studies strongly supports a microsurgical approach for palpable varicoceles to optimize future fertility. Microsurgical varicocelectomy yields a lower incidence of hydrocele (0% vs 2.8% open, 5.4% laparoscopic) and lower recurrence (2.6% vs 11% open, 17% laparoscopic) compared with other techniques ^[34]A1b. A meta-analysis confirmed that microsurgery confers the highest pregnancy rate (OR 1.63, 95% CI 1.19-2.23) and the least morbidity ^[35]A1a. In adolescents with isolated asthenospermia, varicocelectomy improves total motile sperm count (from 29.6 to 39.0 million, p<0.05) and increases spontaneous pregnancy rates (65% vs 32% in controls, p<0.01) ^[74]B3b. The decision to operate should be individualized, weighing the risk of testicular growth arrest against the possibility of spontaneous resolution.

Pregnancy (Female Partner Considerations)

When the female partner is already pregnant, the focus shifts to minimizing risks from any ongoing male infertility treatment. Sperm DNA fragmentation (SDF) is a key predictor of pregnancy loss. High SDF, defined by assay-specific cut-offs, has low sensitivity but high specificity for miscarriage across natural and assisted conception, though its predictive value alone is limited ^[173]B2a. In couples with recurrent pregnancy loss or prior ART failure, SDF testing may be considered ^[187]D5. For men with severe male infertility (e.g., non-obstructive azoospermia, severe oligoasthenospermia), intracytoplasmic sperm injection (ICSI) with or without preimplantation genetic testing for aneuploidy (PGT-A) does not improve live birth rates compared with ICSI alone (48.4% vs 46.2% after first transfer; OR 1.09, 95% CI 0.76-1.58), but PGT-A significantly reduces pregnancy loss (5.8% vs 19.1%; OR 0.26, 95% CI 0.14-0.50) ^[111]A1b. No male infertility medication has been shown to benefit the already pregnant partner; thus, empirical medical therapy should be discontinued during pregnancy.

Elderly Men

Advancing paternal age is associated with increased SDF and reduced cumulative live birth rates. In couples undergoing IVF/ICSI, severe male factor infertility (OAT-S and NOA) is associated with lower fertilization rates (68.1% vs 71.5% for OAT-S, p=0.001) and decreased embryo utilization rates (48.8% vs 57.3% for OAT-S, p<0.001) ^[186]B3b. The impact of varicocele repair in older men has not been specifically studied, but the same predictors of live birth, larger testicular volume, lower FSH, higher inhibin B, likely apply ^[41]B2b. Antioxidant therapy for idiopathic infertility shows small improvements in sperm concentration (SMD 1.09, 95% CI 0.10-2.08) and progressive motility (SMD 1.11, 95% CI 0.32-1.90), but prediction intervals are wide and certainty is very low ^[18]A1a. Vitamin D supplementation may improve progressive motility, but no effect on pregnancy or live birth has been demonstrated ^[89]B2a.

Immunocompromised Men

Men with spinal cord injury (SCI) represent a distinct immunocompromised population requiring assisted ejaculation. Penile vibratory stimulation is first-line, followed by electroejaculation. Despite lower semen volume (1.5 vs 3.1 mL, p<0.01) and poor progressive motility (5% vs 35%, p<0.01), fertilization rates are lower (46% vs 71%, p<0.01), but pregnancy and live birth rates per cycle are not significantly different from controls ^[85]B3b. For men with other causes of immunocompromise (e.g., HIV, transplant recipients), no specific data from the provided literature exist; general principles of minimizing infection risk and optimizing ART timing apply.

Pearl: In elderly men or partners with recurrent pregnancy loss, SDF testing may identify a modifiable cause, but the evidence does not support routine use of antioxidants or PGT-A to improve live birth rates ^{[111]A1b[173]B2a[18]A1a}.

The recognition that male infertility signals elevated long-term health risks transforms the fertility evaluation into an opportunity for preventive medicine. Men with impaired spermatogenesis carry a higher all-cause mortality (HR 1.42, 95% CI 1.27-1.60), with azoospermic men facing a doubling of risk (HR 2.01) ^[174]B2b. This association persists after excluding prevalent cardiovascular disease and cancer, implicating shared genetic, hormonal, and environmental pathways ^[191]D5. The fertility assessment thus becomes a gateway to broader men's health surveillance.

Primary Prevention Strategies

Lifestyle modification remains the cornerstone of primary prevention. Smoking cessation, weight management , and avoidance of environmental toxins (e.g., endocrine disruptors, heavy metals) reduce oxidative stress and preserve semen quality, though effect sizes from randomized trials are modest. Vaccination offers a targeted preventive tool: human papillomavirus (HPV) vaccination in males reduces seminal viral load, improves pregnancy rates, and lowers miscarriage risk in couples attempting conception ^[190]D5. The COVID-19 pandemic was associated with persistent deficits in normal sperm morphology (decline from 88.9% to 55.1% meeting WHO threshold ≥4%) and a modest testosterone suppression (4.46 to 4.19 ng/mL) that did not return to baseline two years post-pandemic ^[188]B3b. While direct evidence for COVID-19 vaccination preventing fertility decline is lacking, vaccination against SARS-CoV-2 is recommended to avoid infection-related reproductive dysfunction.

Screening Recommendations

Screening for genetic causes follows guideline-endorsed thresholds. The EAU guideline recommends Y-chromosome microdeletion (YCM) screening only when sperm concentration is ≤1 million/mL, as the prevalence of complete YCMs in men with >1 million/mL is <1% (0.8% for 1-5 million/mL, 0.5% for 5-20 million/mL) ^[37]C4. Cystic fibrosis transmembrane conductance regulator (CFTR) testing is indicated in men with congenital bilateral absence of the vas deferens or unexplained azoospermia, with a carrier frequency of 1 in 24 in Caucasian populations ^[60]B3b.

Testicular cancer screening is particularly relevant. Incidental small testicular masses (<10 mm) are found in 2.9% of infertile men undergoing scrotal ultrasound; surveillance with interval imaging is safe, with a mean growth rate of -0.01 mm/year and no advanced or recurrent disease in surveilled patients ^[38]B3b. For testicular microlithiasis, isolated findings do not warrant routine surveillance, but when combined with risk factors ( cryptorchidism , infertility, family history of testicular germ cell tumor), periodic ultrasound may be considered within shared decision-making ^[144]B2a. Leydig cell tumors, increasingly detected on imaging, can be managed with active surveillance rather than immediate surgery in compliant patients ^[165]B2b.

Vaccine-Related Considerations

HPV vaccination is recommended for males aged 9-26 years, with emerging evidence that it improves fertility outcomes by reducing seminal HPV load and sperm DNA fragmentation ^[190]D5. The benefit-risk balance strongly favors vaccination; no significant adverse effects on fertility have been reported. COVID-19 vaccination is safe in men attempting conception and may prevent infection-related semen quality decline, though long-term data are still accumulating.

Patient Education Points

Patients should understand that male infertility is a marker for potentially modifiable health vulnerabilities. Education should emphasize regular primary care visits for blood pressure, glucose, and lipid screening; testosterone assessment if symptoms of hypogonadism arise; and testicular self-examination, particularly in men with cryptorchidism or a family history of testicular cancer. After treatment for a correctable cause (e.g., varicocelectomy, hormonal therapy), semen analysis should be repeated at 3- to assess response. Genetic counseling is essential for men with YCM or CFTR mutations to discuss implications for offspring and reproductive options.

Pearl: The sperm concentration threshold for YCM screening has shifted from <5 million/mL to ≤1 million/mL based on meta-analytic evidence that 99% of deletions occur below this level; adopting this threshold avoids unnecessary testing without missing clinically relevant genetic findings ^[37]C4.